SynAct Pharma (STO: SYNACT)

Last close As at 17/01/2026

SEK23.80

−0.15 (−0.63%)

Market capitalisation

SEK1,278m

SynAct Pharma is a clinical-stage biotechnology company focussed on the development of treatments to resolve, rather than inhibit, ongoing inflammatory processes in acute and chronic diseases.

Latest Insights

View More

Healthcare | Update

SynAct Pharma — Approaching a catalyst-rich period

Healthcare | Initiation

SynAct Pharma — Differentiated inflammation resolution approach

Healthcare | podcast

Bull, Bear & Beyond – SynAct Pharma: executive interview

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Jeppe Øvlesen

    CEO

  • Björn Westberg

    CFO